Fifth Third Bancorp grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Analyst Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Dexcom (DXCM – Research Report) and keeping the price target at ...

Dexcom stock has been steadily gaining value since the crash, rising to $85 per share at the time of writing, although this represents a discount of 35% to its price immediately prior to the Q2 ...